BMY ▲ +0.6% - Bristol-Myers Squibb Company $BMY Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma 25-SEP-2026 10:02 AM ET